Treatment of common cutaneous herpes simplex virus infections

American Family Physician

Volumn 61, Issue 6, 2000, Pages 1697-1706+1708

  Emmert, David H ^a  

^a LANCASTER GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; GENITAL HERPES; HERPES LABIALIS; HUMAN; RECURRENT INFECTION; REVIEW; VIRUS DIAGNOSIS;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; DRUG COSTS; HERPES GENITALIS; HERPES LABIALIS; HERPES SIMPLEX; HUMANS; PATIENT EDUCATION; TEACHING MATERIALS; VALINE;

EID: 0343570096     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-55.
2. Annunziato PW, Gershon A. Herpes simplex virus infections. Pediatr Rev 1996;17:415-24.
3. Clark JL, Tatum NO, Noble SL. Management of genital herpes. Am Fam Physician 1995;51:175-82,187-8.
4. Green J, Kocsis A. Psychological factors in recurrent genital herpes. Genitourin Med 1997;73:253-8.
5. Su SJ, Wu HH, Lin YH, Lin HY. Comparative studies of types 1 and 2 herpes simplex virus infection of cultured normal keratinocytes. J Clin Pathol 1995; 48:75-9.
6. Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992;327:782-9 [Published errata in N Engl J Med 1993;328:671 and 1997;337:1703].
7. American College of Obstetricians and Gynecologists. Antimicrobial therapy for obstetric patients. ACOG education bulletin no. 245. Washington, D.C.: ACOG, 1998.
8. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998;134:185-91.
9. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, doseranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996;156:1729-35.
10. Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-10.
11. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996;276:44-9.
12. Mertz GJ, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997;157:343-9.
13. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998;280:887-92.
14. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
15. Mertz GJ. Epidemiology of genital herpes infections. Infect Dis Clin North Am 1993;7:825-39.
16. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-5.
17. Augenbraum M, Feldman J, Chirgwin K, Zenilman J, Clarke L, DeHovitz J, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995;123:845-7.
18. Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, Connor J, et al. Double-blind placebo-comtrolled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984;252:1147-51.
19. Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-6.
20. Faro S. A review of famciclovir in the management of genital herpes. Infect Dis Obstet Gynecol 1998;6:38-43.
21. Patel R, Bodsworth NJ, Woolley P, Peters B, Vejlsgaard G, Saari S, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med 1997;73:105-9.
22. Karadi I, Karpati S, Romics L. Aspirin in the management of recurrent herpes simplex virus infection [Letter]. Ann Intern Med 1998;128:696-7.
23. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997;176:1129-34.
24. Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-7.
25. Kroon S. Genital herpes when and how to treat. Semin Dermatol 1990;9:133-40.
26. Mindel A. Is it meaningful to treat patients with recurrent herpetic infections? Scand J Infect Dis 1991;80(suppl):27-32.
27. Mertz GJ, Eron L, Kaufman R, Goldberg L, Raab B, Conant M, et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med 1988;85:14-9.
28. Sande MA, Armstrong D, Corey L, Drew WL, Gilbert D, Moellering RC Jr, et al. Perspectives on switching oral acyclovir from prescription to over-the-counter status: report of a consensus panel. Clin Infect Dis 1998;26:659-63.
29. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124(1 pt 1):8-15.
30. Straus SE, Rooney JF, Hallahan C. Acyclovir suppresses subclinical shedding of herpes simplex virus [Letter]. Ann Intern Med 1996;125:776-7.
31. Arvin AM, Prober CG. Herpes simplex virus type 2 - a persistent problem [Editorial]. N Engl J Med 1997;337:1158-9.
32. Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 1995;122:889-98 [Published erratum in Ann Intern Med 1995;123:395].
33. Gibson JJ, Hornung CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis 1990;162:306-12.
34. Spruance SL. The natural history of recurrent oralfacial herpes simplex virus infection. Semin Dermatol 1992;11:200-6.
35. Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90.
36. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997;314:1800-3.
37. Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993;(suppl 1):27-32.
38. Raborn GW, McGaw WT, Grace M, Tyrrell LD, Samuels SM. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J Am Dent Assoc 1987;115:38-42.
39. Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D'Ambrosio JA, Bernstein DI. Perioral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999;179:303-10.